FIELD: chemistry.
SUBSTANCE: invention relates to pyrrole derivatives of formula (I): 
, where R1 denotes hydrogen; R2 denotes adamantine which is unsubstituted or substituted with a hydroxy group or halogen; R3 denotes trifluoromethyl, pyrazole, triazole, piperidine, pyrrolidine, hydroxymethylpiperidine, benzylpiperazine, hydroxypyrrolidine, tert-butylpyrrolidine, hydroxyethylpiperazine, hydroxypiperidine or thiomorpholyl group; R4 denotes cyclopropyl, tert-butyl, -CH(CH3)2CH2OH, methyl, -CF3 or -(CH2)nCF3 group, where n equals 1 or 2; R5 denotes hydrogen or lower alkyl which is unsubstituted or substituted with a halogen, as well as pharmaceutically acceptable salts thereof.
EFFECT: compounds and pharmaceutical compositions containing said compounds can inhibit 11β-hydroxysteroid dehydrogenase of the form 1 (11-BETA-HSD-1) and can be used to treat diseases such as type II sugar diabetes type and metabolic syndrome.
17 cl, 99 ex, 1 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| 11β-HYDROXYSTEROID DIHYDROGENASE INHIBITORS | 2008 |
|
RU2440989C2 |
| PYRAZOLES | 2006 |
|
RU2381217C2 |
| BIPIRAZOLE DERIVATIVE | 2007 |
|
RU2470016C2 |
| IMIDAZOLONE AND IMIDAZOLIDINONE DERIVATIVES AS 11B-HSD1 INHIBITORS FOR DIABETES | 2007 |
|
RU2439062C2 |
| PYRROLIDINYL UREA AND PYRROLIDINYL THIOUREA COMPOUNDS AS TRKA KINASE INHIBITORS | 2012 |
|
RU2606131C2 |
| PYRAZOLPYRIMIDINE COMPOUNDS JAK INHIBITORS AND METHODS | 2009 |
|
RU2539568C2 |
| PYRROLE- OR IMIDAZOLE AMIDES FOR WEIGHT-REDUCING TREATMENT | 2005 |
|
RU2380367C2 |
| PYRAZOLAMINOPIRIMIDINE DERIVATIVES AS MODULATORS OF LEUCINE-REPEATING KINASE 2 | 2013 |
|
RU2637947C2 |
| SPHYNGOSINE KINASE INHIBITORS | 2006 |
|
RU2447060C2 |
| THIAZOLOPYRIMIDINONES AS MODULATORS OF NMDA RECEPTOR ACTIVITY | 2014 |
|
RU2703273C2 |
